



October 31, 2016

Akebia to Present at the Credit Suisse 25th Annual Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- [Akebia Therapeutics, Inc.](http://www.akebia.com) (NASDAQ: AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced that John P. Butler, President and Chief Executive Officer, will present at the Credit Suisse 25th Annual Healthcare Conference on Monday, November 7, 2016 at 1:00 p.m. Mountain Time. The conference will take place at The Phoenician in Scottsdale, Arizona.

A live audio webcast of the presentation will be available on the company's website at <http://ir.akebia.com/events.cfm>. Archived presentations will be available for 90 days.

About Akebia Therapeutics

Akebia Therapeutics, Inc. is a biopharmaceutical company headquartered in Cambridge, MA, focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor biology. Akebia's lead product candidate, vadadustat, is an oral therapy in development for the treatment of anemia related to chronic kidney disease in both non-dialysis and dialysis patients. Akebia has commenced its vadadustat Phase 3 program, which includes the PRO₂TECT studies for non-dialysis patients with anemia secondary to chronic kidney disease and INNO₂VATE studies for dialysis-dependent patients. For more information, please visit our website at www.akebia.com.

View source version on [businesswire.com](http://www.businesswire.com): <http://www.businesswire.com/news/home/20161031006065/en/>

Akebia:

AJ Gosselin, 617-844-6130

Manager, Corporate Communications

agosselin@akebia.com

Source: Akebia Therapeutics, Inc.

News Provided by Acquire Media